WeTrials

Phase II Trial of Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer

What is this study?

This study is testing a combination of two targeted medications, Lapatinib and RAD-001, to see how well they work against advanced breast cancer. Researchers want to help patients whose cancer has continued to grow even after trying other treatments.

Who can participate?

You may be able to join if you are an adult woman with HER2-positive breast cancer that has spread, and your cancer has progressed after previous treatments. You must also be able to take pills by mouth and perform normal daily activities.

What will happen?

Participants will take the study medications, Lapatinib and RAD-001, to help block cancer growth. Your health care team will closely monitor you and check how your body responds to the treatment.

Where and when?

This study takes place in Kansas City, Kansas, United States. The current status of the study is not fully active or is unknown, so you should check with the study team for the latest updates.

Key Points
  • 1Tests a combination of Lapatinib and RAD-001 for advanced breast cancer
  • 2Designed for women whose cancer has progressed on past therapies
  • 3Takes place at a location in Kansas City, Kansas

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Metastatic Breast Cancer

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.